Rebif (interferon beta-1a) (DrugBank: Interferon beta-1a, Interferon beta)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02921035 (ClinicalTrials.gov) | June 30, 2016 | 29/9/2016 | Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis | A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a | Relapsing Multiple Sclerosis | Drug: Rebif (Interferon beta-1a) | Merck KGaA, Darmstadt, Germany | Merck Serono Middle East FZ LLC | Completed | 18 Years | 60 Years | All | 594 | Algeria;Argentina;Bahrain;Bulgaria;Egypt;Hungary;Iran, Islamic Republic of;Korea, Republic of;Kuwait;Lebanon;Morocco;Poland;Saudi Arabia;Germany;Tunisia;United Arab Emirates | |
| 2 | NCT02749396 (ClinicalTrials.gov) | May 2, 2016 | 20/4/2016 | EPID Multiple Sclerosis Pregnancy Study | Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon ß - a Register-based Study in the Nordic Countries | Multiple Sclerosis | Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG;Drug: Extavia (interferon beta-1b), Novartis Pharma AG;Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd;Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd;Drug: Avonex (interferon beta-1a), Biogen Idec Ltd;Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046);Other: No MSDMDs therapy (control) | Bayer | EPID Research;Biogen;Merck Serono Europe Ltd;Novartis Pharmaceuticals | Completed | N/A | N/A | Female | 2089 | Finland | |
| 3 | NCT01075880 (ClinicalTrials.gov) | May 2009 | 24/2/2010 | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif (Interferon beta-1a) | Merck KGaA | Merck spol.s.r.o., Czech Republic | Completed | 18 Years | 65 Years | Both | 300 | N/A | Czech Republic |